NCT06708845 - US Zamto-cel Autoimmune Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Lupus NephritisSystemic Lupus ErythematosusSystemic Sclerosis (SSc)Diffuse Cutaneous Systemic Sclerosis

Interventions

BIOLOGICAL

zamtocabtagene autoleucel

chimeric antigen receptor T-cell (CAR-T) therapy

DRUG

Cyclophosphamide

Lymphodepleting chemotherapy

DRUG

Fludarabine

Lymphodepleting chemotherapy